柴胡解毒汤配合重组人干扰素治疗宫颈高危型人乳头瘤病毒感染临床研究

Clinical Study on Chaihu Jiedu Tang Combined with Recombinant Human Interferon for Cervical High-risk Human Papillomavirus Infection

目的:观察柴胡解毒汤配合重组人干扰素治疗宫颈高危型人乳头瘤病毒(HPV)感染的临床疗效。方法:纳入60例肝经湿热型宫颈高危型HPV感染患者作为研究对象,随机将患者分为2组各30例,观察组以柴胡解毒汤联合重组人干扰素治疗,对照组仅予重组人干扰素治疗,比较2组的临床疗效、病毒载量与不良反应发生情况。结果:治疗后,观察组总有效率93.3%,对照组总有效率63.3%,2组比较,差异有统计学意义(P <0.05)。2组的病毒载量均较治疗前降低(P <0.05),观察组病毒载量低于对照组(P <0.05)。观察组不良反应发生率(13.33%)低于对照组(36.67%),差异有统计学意义(P <0.05)。结论:柴胡解毒汤联合重组人干扰素治疗肝经湿热型宫颈高危型HPV感染患者能够提高临床疗效,降低高危型HPV病毒载量,增强免疫力,促进患者恢复,且副作用小,安全可靠。

Objective:To observe the clinical effect of Chaihu Jiedu tang combined with recombinant human interferon for cervical high-risk human papillomavirus(HPV) infection. Methods:Selected 60 cases of patients with cervical high-risk HPV infection of dampness-heat in liver meridian type as study subjects,and divided them into two groups randomly,30 cases in each group. The observation group received Chaihu Jiedu tang combined with recombinant human interferon for treatment,while the control group only received recombinant human interferon. Compared the clinical effect,viral load and the adverse reactions in the two groups. Results:After treatment,the total effective rate was 93.3% in the observation group and was 63.3% in the control group,the difference being significant(P < 0.05). The viral load in the two groups was decreased when compared with that before treatment respectively(P < 0.05),and the viral load in the observation group was lower than that in the control group(P < 0.05). The incidence of adverse reactions was 13.33% in the observation group,lower than that of 36.67% in the control group,the difference being significant(P < 0.05). Conclusion:The therapy of Chaihu Jiedu tang combined with recombinant human interferon for patients with cervical high-risk HPV infection of dampness-heat in liver meridian type can improve the clinical effect,decrease the viral load of high-risk HPV,improve the immunity and promote the recovery of patients with little side effect and high safety.